用于评估类风湿性关节炎的生化和生物标志物的应用进展
Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis.
作者信息
Nakamura R M
机构信息
Department of Pathology, Scripps Clinic, La Jolla, California 92037, USA.
出版信息
J Clin Lab Anal. 2000;14(6):305-13. doi: 10.1002/1098-2825(20001212)14:6<305::aid-jcla10>3.0.co;2-p.
Abstract
Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disorder which is predominant in females. The exact etiology remains undefined. Recently, a large number of biochemical and biologic markers, which are useful in the diagnosis, prognosis, and monitoring therapy of RA, have been reported. The new markers include genetic markers, filaggrin, citrulline containing peptides, A2/RA33, cytokines, joint and collagen breakdown products, and bone turnover markers. No laboratory tests in and of themselves are diagnostic of RA. The new markers have been employed in monitoring RA patients during treatment and following the course of the disease. With the development of innovative therapies for RA, many of the biochemical and biologic markers will be useful.
摘要
类风湿关节炎（RA）是一种慢性全身性炎症性自身免疫性疾病，女性更为常见。确切病因尚不清楚。最近，大量对RA的诊断、预后及治疗监测有用的生化和生物标志物已被报道。新的标志物包括遗传标志物、丝聚蛋白、含瓜氨酸的肽、A2/RA33、细胞因子、关节和胶原蛋白分解产物以及骨转换标志物。没有任何一项实验室检查本身能够确诊RA。这些新标志物已被用于监测RA患者的治疗过程及病情发展。随着RA创新疗法的发展，许多生化和生物标志物将发挥作用。
相似文献
1
Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis.
J Clin Lab Anal. 2000;14(6):305-13. doi: 10.1002/1098-2825(20001212)14:6<305::aid-jcla10>3.0.co;2-p.
2
Rheumatoid factors, anti-filaggrin antibodies and low in vitro interleukin-2 and interferon-gamma production are useful immunological markers for early diagnosis of community cases of rheumatoid arthritis. A preliminary study.
Joint Bone Spine. 2001 Mar;68(2):144-53. doi: 10.1016/s1297-319x(00)00244-x.
3
Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis.
Clin Exp Immunol. 2004 Jan;135(1):173-80. doi: 10.1111/j.1365-2249.2004.02341.x.
4
[Novel autoantibodies for the diagnosis of rheumatoid arthritis].
Z Rheumatol. 2002 Dec;61(6):667-73. doi: 10.1007/s00393-002-0470-y.
5
Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis.
Ann Rheum Dis. 2001 Jan;60(1):67-8. doi: 10.1136/ard.60.1.67.
6
Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications.
Semin Arthritis Rheum. 1994 Jun;23(6):379-87. doi: 10.1016/0049-0172(94)90088-4.
7
[Antibodies to citrullinated proteins in rheumatoid arthritis].
Nihon Rinsho Meneki Gakkai Kaishi. 2006 Apr;29(2):49-56. doi: 10.2177/jsci.29.49.
8
Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Ann N Y Acad Sci. 2005 Jun;1050:295-303. doi: 10.1196/annals.1313.031.
9
[Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
Mikrobiyol Bul. 2003 Apr-Jun;37(2-3):163-70.
10
The use of citrullinated peptides for the diagnosis and prognosis of rheumatoid arthritis.
Curr Top Med Chem. 2014;14(23):2729-33. doi: 10.2174/1568026614666141215152733.
引用本文的文献
1
Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis.
Innate Immun. 2025 Jan-Dec;31:17534259251324820. doi: 10.1177/17534259251324820. Epub 2025 Mar 16.
2
Synovial Fluid Markers and Extracellular Vesicles in Rheumatoid Arthritis.
Medicina (Kaunas). 2024 Nov 26;60(12):1945. doi: 10.3390/medicina60121945.
3
Platelet and Lymphocyte-Related Parameters as Potential Markers of Osteoarthritis Severity: A Cross-Sectional Study.
Biomedicines. 2024 Sep 10;12(9):2052. doi: 10.3390/biomedicines12092052.
4
Neutrophil-to-monocyte ratio is the better new inflammatory marker associated with rheumatoid arthritis activity.
Health Sci Rep. 2023 Aug 2;6(8):e1478. doi: 10.1002/hsr2.1478. eCollection 2023 Aug.
5
Cardiovascular Risk and Serum Hyaluronic Acid: A Preliminary Study in a Healthy Population of Low/Intermediate Risk.
J Clin Lab Anal. 2017 Jan;31(1). doi: 10.1002/jcla.22010. Epub 2016 Jun 16.
6
PADI4 haplotypes in association with RA Mexican patients, a new prospect for antigen modulation.
Clin Dev Immunol. 2013;2013:383681. doi: 10.1155/2013/383681. Epub 2013 Dec 22.
7
Identification and evaluation of novel synovial tissue biomarkers in rheumatoid arthritis by laser scanning cytometry.
Arthritis Res Ther. 2012 Jan 17;14(1):R8. doi: 10.1186/ar3682.
8
Second generation automated anti-CCP test better predicts the clinical diagnosis of rheumatoid arthritis.
J Clin Immunol. 2012 Feb;32(1):131-7. doi: 10.1007/s10875-011-9610-y. Epub 2011 Nov 10.
9
Autoimmunity against fibrinogen mediates inflammatory arthritis in mice.
J Immunol. 2010 Jan 1;184(1):379-90. doi: 10.4049/jimmunol.0901639. Epub 2009 Nov 30.
10
The role of biomarkers in the management of patients with rheumatoid arthritis.
Curr Rheumatol Rep. 2009 Oct;11(5):371-7. doi: 10.1007/s11926-009-0053-x.
本文引用的文献
1
SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS.
J Exp Med. 1930 Sep 30;52(4):561-71. doi: 10.1084/jem.52.4.561.
2
On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939.
APMIS. 2007 May;115(5):422-38; discussion 439. doi: 10.1111/j.1600-0463.2007.apm_682a.x.
3
A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR.
Ann Rheum Dis. 1964 Jul;23(4):302-5. doi: 10.1136/ard.23.4.302.
4
1958 Revision of diagnostic criteria for rheumatoid arthritis.
Bull Rheum Dis. 1958 Dec;9(4):175-6.
5
Gene therapy for rheumatic diseases.
Arthritis Rheum. 1999 Jan;42(1):1-16. doi: 10.1002/1529-0131(199901)42:1<1::AID-ANR1>3.0.CO;2-4.
6
Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis.
Rheumatol Int. 1998;18(3):119-22. doi: 10.1007/s002960050069.
7
Concordant message of different inflammatory markers in patients with rheumatoid arthritis.
Ups J Med Sci. 1998;103(1):35-42. doi: 10.3109/03009739809178943.
8
IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis.
Rheum Dis Clin North Am. 1998 Aug;24(3):629-39. doi: 10.1016/s0889-857x(05)70030-2.
9
Interleukin-1 receptor antagonist.
Rheum Dis Clin North Am. 1998 Aug;24(3):615-28. doi: 10.1016/s0889-857x(05)70029-6.
10
Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.
Rheum Dis Clin North Am. 1998 Aug;24(3):593-614. doi: 10.1016/s0889-857x(05)70028-4.
Zotero 插件